RxDoctor Payments Data

Todd Sheer, MD

Gastroenterology · Durango, CONPI 1568434702

Payments from drug & device makers

$289in general payments, 2019–2025

Across 9 payments — averaging $32.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$100
  • Orphalan Inc$74
  • Boston Scientific$34
  • Merck$25
  • AbbVie$24
  • Regeneron Healthcare Solutions, Inc.$18
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$289100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead1$100
Orphalan Inc2$74
Boston Scientific2$34
Merck1$25
AbbVie1$24
Regeneron Healthcare Solutions, Inc.1$18
Johnson & Johnson1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$289 in reported general payments places this provider in the 25th percentile of 304 gastroenterology providers in Colorado.

See all gastroenterology providers in Colorado

Medicare billing

Part B allowed, 2024
$115,597
Medicare patients
473
Services billed
834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin25$80,084
CreonLipase/Protease/Amylase30$39,320
LinzessLinaclotide15$15,382
MotegrityPrucalopride Succinate14$11,798
Mesalamine20$7,859
Budesonide DrBudesonide17$6,139
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates79$5,565
Ursodiol43$4,549
Esomeprazole Magnesium72$4,470
Sucralfate13$2,071
Rabeprazole Sodium22$1,287
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl74$1,204
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl73$1,177
Omeprazole120$1,062
Azathioprine20$777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$24$54,70245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 304 gastroenterology providers in Colorado.

Other gastroenterology in Durango

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →